ECJ backs UK regulator’s ‘pay-for-delay’ fine levied on GSK

GSK has no immediate plans to spin off Pfizer joint venture

GlaxoSmithKline has made no plans to spin off or float its consumer healthcare joint venture with Pfizer, according to a top company executive.

ViiV’s two-drug HIV therapy Dovato gets Japanese approval

GSK's CEO Walmsley aiming for six new approvals in 2020

GlaxoSmithKline’s CEO Emma Walmsley has said the company hopes to get at least six new drug approvals in the next year.

ViiV files first-in-class HIV drug in Europe

GSK completes travel vaccine offload as revamp continues